Rheumatology Network went to Disney World this month, to learn what's most important to pediatric rheumatology in 2014. Watch for our latest and forthcoming reports on important sessions from ACR's PRSYM, including:
HAQ, CDAI, RAPID3, DAS28: Which outcome measure should you use to track progress in patients with rheumatoid arthritis? Here, a brief review of their differences, and the arguments for a new paradigm in disease assessment.
(ACR Pediatrics 2014) New biologics have revolutionized care for children with juvenile arthritis in recent years. But a pediatric rheumatologist says this progress isn't nearly good enough, urging a much tougher agenda.
People with psoriatic arthritis, particularly women, are more likely than psoriasis-only patients to have depression and/or anxiety. Poorly recognized and treated, this problem may affect the success of treatment for PsA.
(VIDEO) Another dictum from medical school gives way to medical research: Clicking, popping, and locking are not useful for diagnosis and prognosis of suspected meniscal tear in patients over 45. Harvard's Dr. Jeffrey Katz reveals signs that actually are informative in this age group.
(VIDEO) Researchers in Norway used data from an observational study of patients with swollen joints to see how many with early signs of rheumatoid arthritis recovered without any treatment at all, and how quickly.
(ACR Pediatrics 2014) How will the hundreds of new genetic biomarkers being found in rheumatology help us to untangle the web of complex diseases? In a brief podcast, a specialist in both rheumatology and genetics discusses recent and future progress.
(AUDIO) What are immune-like cells doing in the central nervous system? Sending false signals when their controls go awry, as current research implies. Here the lead author of a recent review offers glimpses of a brighter future for relief of chronic pain syndromes.
(AUDIO) A gene defect that causes lupus-like symptoms in a mouse model has turned up as significant in some humans with lupus nephritis, offering a path toward predictive testing. Listen as the lead author reporting this study describes its findings and a timeline toward clinical applications.
More than a third of patients aren't taking DMARDs as guidelines unanimously recommend. Rheumatologist Richard Martin MD reveals insights from new research about why some patients resist the idea, and what you can do to help.